European Archives - Page 958 of 1056 - European Medical Journal

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a…

Biomarker-driven therapies for triple-negative breast cancer

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups…

EMJ

Improving access to innovation in cancer care in Europe

At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology…

Changing the standard of care in previously treated metastatic renal cell carcinoma

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials…

POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy…

Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma

At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia…

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer

At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris…

Deciding which of the available genomic tests to use

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in…

Progress in the treatment of BRAF-mutant melanoma

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the…

BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single…